-+ 0.00%
-+ 0.00%
-+ 0.00%

Gabungan RYBREVANT Johnson & Johnson Memanjangkan Kelangsungan Hidup Ke 34.3 Bulan Dalam Kanser Paru-paru EGFR Exon 20+

Benzinga·09/14/2026 12:41:21

https://www.jnj.com/media-center/press-releases/johnson-johnsons-rybrevant-amivantamab-vmjw-plus-chemotherapy-delivers-longest-reported-median-overall-survival-in-egfr-exon-20-insertion-mutation-positive-lung-cancer